Why Is Pancreaze So Hard to Find? [Explained for 2026]

You hand your prescription to the pharmacist, wait for the text, and then get the call: "We don't have it in stock." If you take Pancreaze (pancrelipase) for exocrine pancreatic insufficiency (EPI), this scenario may feel all too familiar. In 2026, many patients are still struggling to find Pancreaze reliably at their local pharmacy.

This article explains exactly why Pancreaze can be hard to find, what's been driving supply pressures across the entire pancreatic enzyme replacement therapy (PERT) market, and — most importantly — what practical steps you can take to get your prescription filled today.

What Is Pancreaze, and Who Needs It?

Pancreaze is a brand-name prescription medication containing pancrelipase — a mixture of digestive enzymes (lipase, protease, and amylase) derived from porcine (pig) pancreas tissue. It is FDA-approved to treat exocrine pancreatic insufficiency (EPI), a condition where the pancreas cannot produce enough enzymes to properly digest food.

Conditions that can cause EPI include:

• Cystic fibrosis
• Chronic pancreatitis
• Pancreatic cancer
• Pancreatectomy (surgical removal of all or part of the pancreas)
• Other conditions affecting pancreatic function

Without adequate enzyme replacement, patients with EPI cannot absorb fat, protein, or carbohydrates properly — leading to malnutrition, weight loss, fatty stools (steatorrhea), bloating, and abdominal pain. Pancreaze must be taken with every single meal and snack, making it a daily essential rather than an optional medication.

Is There a Pancreaze Shortage in 2026?

Pancreaze is not currently listed on the FDA's official drug shortage list in 2026. However, patients and pharmacies are still experiencing intermittent availability issues, particularly for certain strengths and in some geographic areas. Here's why:

Why Is the Entire PERT Market Under Supply Pressure?

Pancreaze doesn't exist in a vacuum — it competes for pharmacy shelf space and distribution with four other FDA-approved PERT products: Creon (AbbVie), Zenpep, Pertzye, and Viokace. When one product faces supply disruptions, patients and providers scramble to alternatives, putting pressure on the entire category.

Creon — the most widely prescribed PERT in the U.S. — experienced significant supply disruptions that began in late 2022 and continued into 2026, with regional and strength-specific gaps persisting. When patients couldn't get Creon, many were switched to Pancreaze, Zenpep, or Pertzye, straining those supply chains too.

Why Is Pancreaze Itself Hard to Stock?

Several factors make Pancreaze — and all PERT products — challenging to consistently stock at every pharmacy:

• Biological manufacturing complexity. Pancrelipase is sourced from porcine pancreatic tissue. Unlike chemically synthesized drugs, biological products require careful sourcing, extraction, and quality control — each step can introduce supply variability.
• No FDA-approved generic. There is no generic version of Pancreaze — or any pancrelipase product. The biological complexity of manufacturing makes generic development far more difficult than for traditional drugs, meaning limited competition and no generic overflow to fill supply gaps.
• Multiple strengths. Pancreaze comes in six different strengths (from 2,600 to 37,000 lipase units per capsule). Pharmacies must stock all variants, and certain strengths may run out faster depending on local patient populations.
• High daily usage. EPI patients take Pancreaze with every meal and snack — often 3–5 times per day. This creates high per-patient volume demands compared to medications taken once daily.
• Limited pharmacy stocking. Not every pharmacy carries all six strengths. Smaller pharmacies may stock only the most common doses, and chain pharmacies may have variable distribution depending on the region.

Can You Switch to a Different PERT If Pancreaze Is Unavailable?

Technically yes — but only with your doctor's guidance. Pancreaze is not interchangeable with other pancrelipase products like Creon or Zenpep. Although they all contain lipase, protease, and amylase, the specific amounts per capsule differ significantly between brands. Switching requires a new prescription specifying the equivalent dose in the new product.

Never stop taking your enzyme replacement therapy or switch brands on your own. Going without PERT can cause rapid nutrient malabsorption and serious health consequences. If you need to switch, call your prescriber first.

What Should You Do If Your Pharmacy Doesn't Have Pancreaze?

Here are practical steps to take when your pharmacy can't fill your Pancreaze prescription:

1. Use medfinder to check nearby pharmacies. medfinder calls pharmacies near you to find out which ones can fill your Pancreaze prescription — saving you the hassle of calling around yourself.
2. Try independent or specialty pharmacies. Large chain pharmacies often have the least flexibility in their ordering systems. Independent pharmacies and specialty pharmacies frequently have access to different distributors and may carry harder-to-find strengths.
3. Ask about neighboring pharmacies. A pharmacy in your network may be out of stock, but a branch on the other side of town might have it. Ask if they can transfer your prescription or check sister locations.
4. Contact your prescriber. Your doctor or NP can help you determine if an alternative PERT is appropriate while Pancreaze is unavailable, and can write the equivalent prescription for Creon, Zenpep, or another PERT.
5. Refill early when possible. Don't wait until you're out. If your insurance allows, request a refill a few days before you run low. This gives your pharmacy time to order in if they need to.

Is Pancreaze Getting Easier to Find?

As of 2026, Pancreaze is not on the FDA's shortage list, and VIVUS reports that the medication is covered on 81% of commercial insurance plans. Availability has generally stabilized compared to the acute supply pressures of 2022–2024. However, intermittent regional gaps and strength-specific shortfalls remain a reality for many patients.

The underlying factors — no generic competition, complex porcine sourcing, high daily usage volumes — are structural challenges that won't disappear quickly. Planning ahead is the most reliable strategy for EPI patients.

The Bottom Line

Pancreaze is a critical medication for people with EPI — going without it is not an option. While it isn't currently in an official FDA shortage, supply inconsistencies across pharmacies and strengths are real. Your best tools are proactive refilling, pharmacy network expansion, and services like medfinder that do the legwork for you. For more on finding it, see our guide on how to find Pancreaze in stock near you.

If you've been unable to get Pancreaze for several days, don't wait — talk to your prescriber today. You can also read our article on alternatives to Pancreaze if you can't fill your prescription.